Contents:
Document Title
Clinical Guideline for Commencing Levetiracetam via Syringe Driver
Document Date
March 2021
Document Purpose and Intended Audience
This guideline has been produced to support the conversion or commencement of levetiracetam via continuous subcutaneous syringe driver in adult patients with a palliative diagnosis.
For use by palliative medicine specialists.
Authors
Dr Kate Holyhead
Dr Sharon Twigger
Consultation Process
Endorsed and approved by SPAGG
Monitoring
This guideline will be audited by members of the SPAGG group.
Review Date
(must be within three years)
March 2025
Approval Signatures:
SPAGG chair
Dr Jon Tomas
SPAGG secretary
Dr Alice Gray
Date Approved by SPAGG: March 2018
Date submitted to Area Prescribing Committee: N/A
Version History
Version 1
Date
March 2018
Summary of change/ process
Endorsed and approved by SPAGG
Version 2
Date
March 2021
Summary of change/ process
Endorsed and approved by SPAGG
Disclaimer
These Guidelines are intended for use by healthcare professionals and the expectation is that they will use clinical judgement, medical, and nursing knowledge in applying the general principles and recommendations contained within. They are not meant to replace the many available texts on the subject of palliative care.
Some of the management strategies describe the use of drugs outside their licensed indications. They are, however, established and accepted good practice. Please refer to the current BNF for further guidance.
Whilst SPAGG takes every care to compile accurate information , we cannot guarantee its correctness and completeness, and it is subject to change. We do not accept responsibility for any loss, damage or expense resulting from the use of this information.